TY - CHAP A1 - Ota Fuchs ED1 - Ota Fuchs Y1 - 2021-07-28 PY - 2021 T1 - Introductory Chapter: Oral Selinexor, a Selective Inhibitor of Nuclear Export in the Treatment of Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents and Monoclonal Antibodies N2 - This book deals with the diagnosis and treatment of multiple myeloma. Multiple myeloma is a plasma cell disorder, the prognosis of which has dramatically improved in the last years thanks to new immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, in relapsed/refractory disease and a diagnosis. Chapters cover such topics as prognostic and predictive factors in newly diagnosed multiple myeloma, treatment approaches, antibody therapies, and three-dimensional (3D) models mimicking multiple myeloma bone marrow–microenvironment interactions. BT - Multiple Myeloma SP - Ch. 1 UR - https://doi.org/10.5772/intechopen.96945 DO - 10.5772/intechopen.96945 SN - 978-1-83968-621-4 PB - IntechOpen CY - Rijeka Y2 - 2021-10-24 ER -